shutterstock_1548704417_nitpicker
nitpicker / Shutterstock.com
18 January 2022AmericasAlex Baldwin

Bristol Myers can’t convince circuit to overturn $1.2bn ruling

The US Court of Appeals for the Federal Circuit has turned down a Bristol Myers Squibb subsidiary’s appeal to overturn a controversial $1.2 billion patent verdict loss against Kite Pharma.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Big Pharma
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More on this story

Big Pharma
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Big Pharma
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.

More on this story

Big Pharma
3 August 2023   Joint stipulations approved by federal judge to dismiss three lawsuits alleging patent infringement on cancer immunotherapies | Companies settle early ‘to save time and attention’ say reports.
Big Pharma
16 June 2022   BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.
Americas
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.